Consensus recommendations of pharmacological management of core symptoms.

Evidence from clinical trials to date has not demonstrated clear efficacy for the use for any agent in the routine management of ASD core symptoms. (S)

There is some evidence for the use of risperidone and aripiprazole in the management of repetitive behaviours, but in view of the potential adverse effects, routine use is not recommended for treating repetitive behaviours. If used, clinicians should weigh up the risks and benefits and re-evaluate these regularly. (B)